Ashok Leyland's Q4 net sales are expected to increase by 35% YoY to Rs 11,786 crore, with net profit likely to decline 10% to Rs 807 crore. NMDC's Q4 revenue is expected to be in the range of Rs 5,789 crore, down 14% YoY, but profit is likely to jump 75% QoQ. Biocon's Q4 net sales are expected to rise 51%, with net profit likely to fall 58% to Rs 100 crore due to last year's quarter's high base. Biocon's biologics sales are predicted to double YoY to Rs 1900 crore.